EdgarLookup

BILL Holdings, Inc. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that BILL Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
1.6%
Profit Margin
Net income ÷ revenue
0.2%
Return on Assets
Net income ÷ assets
1.57x
Debt-to-Equity
Total liabilities ÷ equity
+13.4%
Revenue Growth
Year over year

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $1.46B Aug 28, 2025
FY2025 Jun 30, 2024 $1.29B Aug 28, 2025
FY2025 Jun 30, 2023 $1.06B Aug 28, 2025
FY2024 Jun 30, 2022 $641.96M Aug 23, 2024
FY2022 Sep 30, 2021 $118.35M May 26, 2023
FY2023 Jun 30, 2021 $238.27M Aug 29, 2023
FY2020 Jun 30, 2020 $42.11M Aug 31, 2020
FY2020 Mar 31, 2020 $41.23M Aug 31, 2020
FY2020 Dec 31, 2019 $39.08M Aug 31, 2020
FY2020 Sep 30, 2019 $35.18M Aug 31, 2020

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $1.19B Aug 28, 2025
FY2025 Jun 30, 2024 $1.06B Aug 28, 2025
FY2025 Jun 30, 2023 $864.49M Aug 28, 2025
FY2024 Jun 30, 2022 $496.96M Aug 23, 2024
FY2023 Jun 30, 2021 $176.46M Aug 29, 2023
FY2020 Jun 30, 2020 $32.01M Aug 31, 2020
FY2020 Mar 31, 2020 $31.12M Aug 31, 2020
FY2020 Dec 31, 2019 $29.29M Aug 31, 2020
FY2020 Sep 30, 2019 $26.03M Aug 31, 2020
FY2020 Jun 30, 2019 $23.20M Aug 31, 2020

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $23.80M Aug 28, 2025
FY2025 Jun 30, 2024 ($28.88M) Aug 28, 2025
FY2025 Jun 30, 2023 ($223.73M) Aug 28, 2025
FY2024 Jun 30, 2022 ($326.36M) Aug 23, 2024
FY2022 Sep 30, 2021 ($74.26M) May 26, 2023
FY2023 Jun 30, 2021 ($98.72M) Aug 29, 2023
FY2020 Jun 30, 2020 ($9.50M) Aug 31, 2020
FY2020 Mar 31, 2020 ($8.32M) Aug 31, 2020
FY2020 Dec 31, 2019 ($7.58M) Aug 31, 2020
FY2020 Sep 30, 2019 ($5.70M) Aug 31, 2020

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 ($80.60M) Aug 28, 2025
FY2025 Jun 30, 2024 ($174.16M) Aug 28, 2025
FY2025 Jun 30, 2023 ($295.77M) Aug 28, 2025
FY2024 Jun 30, 2022 ($316.82M) Aug 23, 2024
FY2023 Jun 30, 2021 ($113.97M) Aug 29, 2023
FY2020 Jun 30, 2020 ($10.26M) Aug 31, 2020
FY2020 Mar 31, 2020 ($9.72M) Aug 31, 2020
FY2020 Dec 31, 2019 ($7.94M) Aug 31, 2020
FY2020 Sep 30, 2019 ($6.28M) Aug 31, 2020
FY2020 Jun 30, 2019 ($5.15M) Aug 31, 2020

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $340.06M Aug 28, 2025
FY2025 Jun 30, 2024 $336.75M Aug 28, 2025
FY2025 Jun 30, 2023 $314.63M Aug 28, 2025
FY2024 Jun 30, 2022 $219.82M Aug 23, 2024
FY2023 Jun 30, 2021 $89.50M Aug 29, 2023
FY2020 Jun 30, 2020 $14.93M Aug 31, 2020
FY2020 Mar 31, 2020 $13.97M Aug 31, 2020
FY2020 Dec 31, 2019 $12.99M Aug 31, 2020
FY2020 Sep 30, 2019 $11.52M Aug 31, 2020
FY2020 Jun 30, 2019 $9.45M Aug 31, 2020

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $350.64M Aug 28, 2025
FY2025 Jun 30, 2024 $278.77M Aug 28, 2025
FY2025 Jun 30, 2023 $187.77M Aug 28, 2025
FY2024 Jun 30, 2022 ($18.09M) Aug 23, 2024
FY2023 Jun 30, 2021 $4.62M Aug 29, 2023
FY2022 Jun 30, 2020 ($4.43M) May 26, 2023
FY2021 Jun 30, 2019 ($3.95M) Aug 30, 2021
FY2020 Jun 30, 2018 ($8.36M) Aug 31, 2020

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $4.34M Aug 28, 2025
FY2025 Jun 30, 2024 $976.0K Aug 28, 2025
FY2025 Jun 30, 2023 $7.59M Aug 28, 2025
FY2024 Jun 30, 2022 $5.38M Aug 23, 2024
FY2023 Jun 30, 2021 $18.90M Aug 29, 2023
FY2022 Jun 30, 2020 $11.44M May 26, 2023
FY2021 Jun 30, 2019 $2.74M Aug 30, 2021
FY2020 Jun 30, 2018 $1.31M Aug 31, 2020

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $10.06B Aug 28, 2025
FY2025 Jun 30, 2024 $9.18B Aug 28, 2025
FY2024 Jun 30, 2023 $9.64B Aug 23, 2024
FY2023 Jun 30, 2022 $9.26B Aug 29, 2023
FY2022 Jun 30, 2021 $5.97B May 26, 2023
FY2021 Jun 30, 2020 $2.40B Aug 30, 2021
FY2020 Jun 30, 2019 $1.53B Aug 31, 2020

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $6.15B Aug 28, 2025
FY2025 Jun 30, 2024 $5.04B Aug 28, 2025
FY2024 Jun 30, 2023 $5.55B Aug 23, 2024
FY2023 Jun 30, 2022 $5.21B Aug 29, 2023
FY2022 Jun 30, 2021 $3.44B May 26, 2023
FY2021 Jun 30, 2020 $1.69B Aug 30, 2021
FY2020 Jun 30, 2019 $1.35B Aug 31, 2020

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $3.91B Aug 28, 2025
FY2025 Jun 30, 2024 $4.13B Aug 28, 2025
FY2025 Jun 30, 2023 $4.09B Aug 28, 2025
FY2025 Jun 30, 2022 $4.04B Aug 28, 2025
FY2024 Jun 30, 2021 $2.53B Aug 23, 2024
FY2023 Jun 30, 2020 $710.72M Aug 29, 2023
FY2022 Jun 30, 2019 ($102.66M) May 26, 2023
FY2021 Jun 30, 2018 ($101.90M) Aug 30, 2021
FY2020 Jun 30, 2017 ($96.83M) Aug 31, 2020

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $2.40B Aug 28, 2025
FY2025 Jun 30, 2024 $2.40B Aug 28, 2025
FY2024 Jun 30, 2023 $2.40B Aug 23, 2024
FY2024 Jun 30, 2022 $2.36B Aug 23, 2024
FY2023 Jun 30, 2021 $1.77B Aug 29, 2023
FY2022 Jun 30, 2020 $0 May 26, 2023

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 ($1.51B) Aug 28, 2025
FY2025 Jun 30, 2024 ($1.10B) Aug 28, 2025
FY2024 Jun 30, 2023 ($856.17M) Aug 23, 2024
FY2023 Jun 30, 2022 ($544.83M) Aug 29, 2023
FY2022 Jun 30, 2021 ($247.47M) May 26, 2023
FY2021 Jun 30, 2020 ($148.75M) Aug 30, 2021
FY2020 Jun 30, 2019 ($117.66M) Aug 31, 2020

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $1.04B Aug 28, 2025
FY2025 Jun 30, 2024 $985.94M Aug 28, 2025
FY2025 Jun 30, 2023 $1.62B Aug 28, 2025
FY2024 Jun 30, 2022 $1.60B Aug 23, 2024
FY2023 Jun 30, 2021 $509.62M Aug 29, 2023
FY2022 Jun 30, 2020 $573.64M May 26, 2023
FY2021 Jun 30, 2019 $90.31M Aug 30, 2021
FY2020 Jun 30, 2018 $22.40M Aug 31, 2020

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $1.71B Aug 28, 2025
FY2025 Jun 30, 2024 $914.00M Aug 28, 2025
FY2024 Jun 30, 2023 $1.84B Aug 23, 2024
FY2023 Jun 30, 2022 $1.77B Aug 29, 2023
FY2022 Jun 30, 2021 $989.38M May 26, 2023

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 0 Aug 28, 2025
FY2025 Jun 30, 2024 0 Aug 28, 2025
FY2025 Jun 30, 2023 (2) Aug 28, 2025
FY2024 Jun 30, 2022 (3) Aug 23, 2024
FY2022 Sep 30, 2021 0 May 26, 2023
FY2023 Jun 30, 2021 (1) Aug 29, 2023
FY2022 Jun 30, 2020 0 May 26, 2023

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 0 Aug 28, 2025
FY2025 Jun 30, 2024 0 Aug 28, 2025
FY2025 Jun 30, 2023 (2) Aug 28, 2025
FY2024 Jun 30, 2022 (3) Aug 23, 2024
FY2022 Sep 30, 2021 0 May 26, 2023
FY2023 Jun 30, 2021 (1) Aug 29, 2023
FY2022 Jun 30, 2020 0 May 26, 2023

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 103.01M Aug 28, 2025
FY2025 Jun 30, 2024 106.65M Aug 28, 2025
FY2024 Jun 30, 2023 106.55M Aug 23, 2024
FY2023 Jun 30, 2022 104.73M Aug 29, 2023
FY2022 Jun 30, 2021 94.50M May 26, 2023